Category: 3. Business

  • Oil extends gains after OPEC+ pauses Q1 output hikes

    Oil extends gains after OPEC+ pauses Q1 output hikes

    Oil prices climbed in early Asian trade on Monday after OPEC+ decided to hold off production hikes in the first quarter of next year.

    Olga Rolenko | Moment | Getty Images

    Oil prices climbed in early Asian trade on Monday after OPEC+ decided to hold off production hikes in the first quarter of next year, easing rising fears of a supply glut.

    Brent crude futures rose 47 cents, or 0.73%, to $65.24 a barrel by 2336 GMT after closing 7 cents higher on Friday. U.S. West Texas Intermediate crude was at $61.43 a barrel, up 45 cents, or 0.74%, after settling up 41 cents in the previous session.

    The Organization of the Petroleum Exporting Countries and their allies, known as OPEC+, agreed on Sunday to raise output by 137,000 barrels per day in December, the same as for October and November.

    “Beyond December, due to seasonality, the eight countries also decided to pause the production increments in January, February, and March 2026,” the group said in a statement.

    RBC Capital analyst Helima Croft said: “There is ample ground for a cautious approach given the uncertainty over the Q1 supply picture and the anticipated demand softness.”

    She added that Russia remains a key supply wild card in the wake of the U.S. imposing sanctions on Rosneft and Lukoil as well as the ongoing strikes on Russian energy infrastructure.

    A Ukrainian drone attack struck on Sunday the Tuapse port, one of Russia’s main Black Sea oil ports, causing a fire and damaging at least one ship.

    Brent and WTI fell more than 2% for a third straight month in October, hitting a five-month low on October 20 on fears of a supply glut and economic concerns about U.S. tariffs.

    Analysts are holding their oil price forecasts largely unchanged as rising OPEC+ output and lackluster demand offset geopolitical risks to supply, a Reuters poll showed. Estimates of oil market surplus ranged anywhere from 0.19 to 3 million bpd.

    The Energy Information Administration reported on Friday that U.S. crude oil output rose 86,000 bpd to a record 13.8 million bpd in August.

    On Friday, President Donald Trump denied he was considering strikes inside Venezuela amid intensifying expectations that Washington may soon expand drug-trafficking-related operations.

    Continue Reading

  • Some Chinese EV Makers’ Shares Rise Sharply on Robust Sales

    Some Chinese EV Makers’ Shares Rise Sharply on Robust Sales

    By Jiahui Huang 

    
  Shares of several Chinese electric-vehicle makers surged sharply Monday, after they reported robust October sales over the weekend. 
    

    
  XPeng and NIO rose 3.8% and 2.9%, respectively by midday, after XPeng delivered a record high 42,013 units in October. NIO also posted a record sales for the month, at 40,397 units, up 93% compared with the same period a year earlier. 
    

    
  Xiaomi's shares gained 3.5% after news its delivered more than 40,000 units last month. Zhejiang Leapmotor's shares rose 0.8% after it said October sales were 84% higher at 70,289 units. 
    

    
  Zeekr Group, which is being taken private by its parent, Geely Automobile, posted strong sales of 21,423 units. 
    

    
  The auto giant BYD sold 441,706 units last month. Its shares fell 2.4% in Hong Kong weighed by news of lower net profit and revenue in the third quarter. 
    

    
  Chinese auto sector is seeing some recovery in demand as the peak season for sales approaches and as auto makers try to clear inventories in the final quarter of the year. 
    

    
  Write to Jiahui Huang at jiahui.huang@wsj.com 
    

    
  (END) Dow Jones Newswires
    

    
  November 02, 2025 23:21 ET (04:21 GMT)
    

    Copyright (c) 2025 Dow Jones & Company, Inc.

    Continue Reading

  • Akeso’s Ivonescimab Secures Fourth Breakthrough Therapy Designation in China for First-Line Treatment of Triple-Negative Breast Cancer

    HONG KONG, Nov. 2, 2025 /PRNewswire/ — Akeso (9926.HK) announced that its first-in-class bispecific antibody, ivonescimab (PD-1/VEGF bispecific antibody), in combination with chemotherapy for first-line treatment of triple-negative breast cancer (TNBC) has been granted Breakthrough Therapy Designation (BTD) by the Center for Drug Evaluation (CDE) from China’s National Medical Products Administration (NMPA).

    The Phase III multicenter, randomized, double-blind clinical trial (HARMONi-BC1/AK112-308) for this combination therapy is ongoing in China. The BTD designation is expected to further expedite the clinical development and regulatory approval process of ivonescimab for the treatment of TNBC. This marks the fourth BTD granted by the CDE for ivonescimab. The previous three designations include:

    • Ivonescimab combined with chemotherapy for locally advanced or metastatic NSCLC resistant to EGFR-TKI therapy, which has now been approved for marketing in China and added to China’s National Reimbursement Drug List.
    • First-line treatment of PD-L1-positive locally advanced or metastatic NSCLC, which has also been approved for marketing in China.
    • Ivonescimab combined with docetaxel for locally advanced or metastatic NSCLC patients who have failed previous PD-1/L1 inhibitors and platinum-based chemotherapy. The Phase III clinical trial for this indication in China is currently ongoing.

    Receiving four Breakthrough Therapy Designations affirms ivonescimab’s substantial clinical benefit across multiple major cancer types and reinforces Akeso’s commitment to addressing critical unmet medical needs. The therapy is currently advancing in 14 Phase III clinical trials worldwide, including four international multicenter studies. These large pivotal studies, backed by repeated regulatory recognition, position ivonescimab to deliver transformative, life-saving outcomes for patients worldwide.

    Forward-Looking Statement of Akeso, Inc.
    This announcement by Akeso, Inc. (9926.HK, “Akeso”) contains “forward-looking statements”. These statements reflect the current beliefs and expectations of Akeso’s management and are subject to significant risks and uncertainties. These statements are not intended to form the basis of any investment decision or any decision to purchase securities of Akeso. There can be no assurance that the drug candidate(s) indicated in this announcement or Akeso’s other pipeline candidates will obtain the required regulatory approvals or achieve commercial success. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

    Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in P.R.China, the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Akeso’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Akeso’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

    Akeso does not undertake any obligation to publicly revise these forward-looking statements to reflect events or circumstances after the date hereof, except as required by law.

    About 依达方 ® (PD-1/VEGF Bispecific, Ivonescimab)

    Ivonescimab is a first-in-class, PD-1/VEGF bispecific immuno-oncology agent developed by Akeso. In May 2024, it received approval from the China National Medical Products Administration (NMPA) for the treatment of locally advanced or metastatic non-squamous non-small cell lung cancer (nsq-NSCLC) after EGFR-TKI therapy. This approval made ivonescimab the world’s first bispecific antibody based on a synergistic “immunotherapy plus anti-angiogenesis” mechanism. In November 2024, ivonescimab was also included in China’s National Reimbursement Drug List (NRDL).

    Additionally, ivonescimab has been approved as a first-line treatment for advanced NSCLC with positive PD-L1 expression. In the Phase III HARMONi-2 study, ivonescimab demonstrated superior efficacy compared to pembrolizumab, resulting in significantly improved clinical outcomes.

    In 2025, the final overall survival (OS) analysis from the HARMONi-A study showed that ivonescimab met the OS endpoint, providing clinically meaningful and statistically significant OS benefits. As the first final OS analysis in a Phase III trial of ivonescimab, these results reaffirm the agent’s groundbreaking value in both progression-free survival (PFS) and overall survival for patients. Moreover, a head-to-head Phase III trial comparing ivonescimab plus chemotherapy to tislelizumab plus chemotherapy in first-line treatment for squamous NSCLC also yielded promising results. These findings position ivonescimab as a substantial clinical breakthrough whether in comparison to PD-1 monotherapy in immuno-oncology, the current standard of care (SOC) of PD-1 inhibitors combined with chemotherapy, or VEGF-targeted therapies in the anti-angiogenesis field. This underscores ivonescimab’s significant potential in cancer treatment.

    As ivonescimab continues to demonstrate substantial clinical value and the potential to redefine treatment standards, its presence in key immuno-oncology indications is expanding rapidly. In lung cancer, the most prevalent cancer globally, ivonescimab is currently involved in 8 registrational/Phase III clinical studies, including:

    • First-line NSCLC (squamous and non-squamous, compared to pembrolizumab + chemotherapy, international multicenter)
    • First-line squamous NSCLC (compared to tislelizumab + chemotherapy)
    • NSCLC after EGFR-TKI progression (HARMONi-A and HARMONi)
    • First-line PD-L1-positive NSCLC (compared to pembrolizumab)
    • First-line PD-L1-highly expressed NSCLC (compared to pembrolizumab)
    • IO-resistant NSCLC
    • Consolidation therapy for limited-stage small cell lung cancer post-concurrent chemoradiotherapy

    In other major tumor types, ivonescimab is rapidly advancing first-line indications with ongoing Phase III trials in:

    • First-line biliary tract cancer (compared to durvalumab + chemotherapy)
    • First-line PD-L1–positive head and neck squamous cell carcinoma in combination with ligufalimab (CD47) (compared to pembrolizumab)

    In the challenging area of cold tumors, ivonescimab has received its fourth Breakthrough Therapy Designation for first-line triple-negative breast cancer. Additionally, Phase III studies are underway for first-line MSS/pMMR colorectal cancer (which accounts for 95% of CRC cases) and first-line pancreatic cancer. Further Phase III studies are also being prepared.

    With nearly 20 Phase II studies across more than 10 additional indications, ivonescimab has established a robust data foundation to support the rapid global expansion of Phase III trials.

    About Akeso
    Akeso (HKEX: 9926.HK) is a leading biopharmaceutical company committed to the research, development, manufacturing and commercialization of the world’s first or best-in-class innovative biological medicines. Founded in 2012, the company has created a unique integrated R&D innovation system with the comprehensive end-to-end drug development platform (ACE Platform) and bi-specific antibody drug development technology (Tetrabody) as the core, a GMP-compliant manufacturing system and a commercialization system with an advanced operation mode, and has gradually developed into a globally competitive biopharmaceutical company focused on innovative solutions. With fully integrated multi-functional platform, Akeso is internally working on a robust pipeline of over 50 innovative assets in the fields of cancer, autoimmune disease, inflammation, metabolic disease and other major diseases. Among them, 24 candidates have entered clinical trials (including 15 bispecific/multispecific antibodies and bispecific ADCs. Additionally, 7 new drugs are commercially available. Through efficient and breakthrough R&D innovation, Akeso always integrates superior global resources, develops the first-in-class and best-in-class new drugs, provides affordable therapeutic antibodies for patients worldwide, and continuously creates more commercial and social values to become a global leading biopharmaceutical enterprise.

    For more information, please visit https://www.akesobio.com/en/about-us/corporate-profile/ and follow us on Linkedin.

    SOURCE Akeso, Inc.

    Continue Reading

  • Evolution Trial Evaluates Radiotherapy-Free Chemoimmunotherapy with Pembrolizumab in Locally Advanced NSCLC with High PD-L1 Expression

    Evolution Trial Evaluates Radiotherapy-Free Chemoimmunotherapy with Pembrolizumab in Locally Advanced NSCLC with High PD-L1 Expression

    The Evolution trial (WJOG11819L) was designed to test whether radiotherapy could be safely omitted in selected patients with unresectable, locally advanced non-small-cell lung cancer (NSCLC) exhibiting high PD-L1 expression (TPS ≥50%). This patient population represents an immunologically distinct subgroup known to derive substantial benefit from PD-1 blockade, as demonstrated in prior pivotal studies such as KEYNOTE-024, -042, -189, and -407, which established pembrolizumab-based regimens as the foundation of systemic therapy in advanced NSCLC.

    In this phase 2, multicentre, single-arm study, investigators sought to determine whether pembrolizumab combined with platinum-based chemotherapy, administered without radiotherapy, could achieve durable disease control and survival outcomes comparable to the standard chemoradiotherapy followed by durvalumab consolidation used in the PACIFIC trial. The rationale was to explore a radiotherapy-free, chemoimmunotherapy approach that could reduce treatment-related toxicities such as pneumonitis and esophageal injury—complications that frequently limit the feasibility of curative-intent chemoradiation and preclude up to one-third of patients from receiving consolidation immunotherapy.

    Study Design and Methods

    This multicentre, single-arm, phase 2 trial was conducted across nine Japanese centers under the West Japan Oncology Group (WJOG).
    Eligible patients were adults (≥20 years) with unresectable, locally advanced stage IIIA–IIIC NSCLC, PD-L1 TPS ≥50%, ECOG performance status 0–1, and no prior systemic therapy. All had an indication for definitive chemoradiotherapy but received a radiotherapy-free regimen instead.

    Treatment protocol:

    Induction therapy (4 cycles): Pembrolizumab 200 mg every 3 weeks + platinum-based doublet chemotherapy

    • Non-squamous: Cisplatin or carboplatin + pemetrexed
    • Squamous: Carboplatin + nab-paclitaxel

    Maintenance therapy: Pembrolizumab (± pemetrexed) every 3 weeks for up to 2 years.

    • Primary endpoint: 2-year progression-free survival (PFS)
    • Secondary endpoints: Objective response rate (ORR), overall survival (OS), duration of response (DOR), and safety.
    • Statistical threshold: A 2-year PFS rate ≥20% was considered clinically meaningful; ≥45% was expected based on PACIFIC trial benchmarks.

    Results

    Between May 18, 2020, and February 22, 2022, a total of 21 patients were enrolled in the Evolution trial. The median age was 73 years, and 76% were male. All patients received pembrolizumab combined with carboplatin-based chemotherapy, followed by maintenance pembrolizumab. Nearly half of the patients (48%) were able to complete the full 2-year course of maintenance therapy. The median follow-up period was 32.5 months, allowing for mature outcome assessment.

    Efficacy Outcomes

    The primary endpoint was met, demonstrating strong and durable disease control:

    The 2-year progression-free survival (PFS) rate was 67% (90% CI 46–83).
    The median PFS was not reached, indicating that many patients remained progression-free at data cutoff.
    The median overall survival (OS) was 44.4 months (32.5–NR), with a 2-year OS rate of 81%.
    Tumor response was robust. The objective response rate (ORR) was 81%, including 8 complete responses and 9 partial responses. Moreover, two-thirds of patients (67%) achieved deep responses, defined as ≥80% tumor shrinkage. These deep responders had markedly improved outcomes, with a 2-year PFS of 86% compared to 29% in non-deep responders (p = 0.0173), suggesting a strong association between depth of response and long-term disease control.

    Evolution trial

    PD-L1 Expression and Outcomes

    Efficacy appeared closely related to the level of PD-L1 expression:

    In patients with PD-L1 TPS 80–100%, the 2-year PFS was 75%, OS was 92%, and ORR reached 92%.
    In contrast, those with PD-L1 TPS 50–79% had lower rates—PFS 56%, OS 67%, and ORR 67%.
    These findings indicate that patients with ultra-high PD-L1 expression (≥80%) experienced the greatest and most durable benefit, reinforcing PD-L1 TPS as a predictive biomarker for selecting candidates who may achieve long-term remission with this radiotherapy-free chemoimmunotherapy approach.

    Safety

    All 21 patients in the Evolution trial experienced at least one adverse event during treatment, reflecting the expected toxicity profile of combination chemoimmunotherapy. Grade 3 or higher adverse events occurred in 62% of patients, while serious adverse events were reported in 33%. The most frequently observed severe toxicities were neutropenia (38%), leukopenia (19%), and pneumonia (14%), which were consistent with known effects of platinum-based chemotherapy.

    Immune-related adverse events (irAEs) were documented in 33% of patients, with grade 3 or higher events in 14%. The most common immune-mediated toxicities included pneumonitis (10%), adrenal insufficiency (5%), and colitis (10%). Importantly, these immune-related events were manageable with corticosteroids and treatment interruption, and no treatment-related deaths were reported.

    Overall, 24% of patients discontinued therapy due to adverse events; however, an intriguing observation emerged—three patients who stopped treatment because of immune-related toxicities, such as grade 2–3 pneumonitis or colitis, continued to experience durable disease control lasting beyond two years. This finding supports the concept that a strong immune response, even when accompanied by immune-related toxicity, may correlate with sustained anti-tumor activity and long-term remission in patients treated with immune checkpoint inhibitors.

    Interpretation

    The Evolution trial provides the first prospective evidence supporting a radiotherapy-free, chemoimmunotherapy approach in unresectable, locally advanced NSCLC with high PD-L1 expression.
    Pembrolizumab combined with platinum doublets achieved 2-year PFS and OS rates comparable or superior to historical chemoradiotherapy data with durvalumab consolidation (PACIFIC trial: ~50% 2-year PFS).
    The durable responses and survival plateaus observed, particularly among deep responders and PD-L1 ≥80%subgroups, indicate potential curative intent with systemic immunochemotherapy alone.

    This approach could represent a less toxic alternative for patients at high risk of radiation-induced morbidity or those ineligible for concurrent chemoradiotherapy. However, the single-arm design and small sample size necessitate randomized validation against the PACIFIC regimen.

    Evolution trial

    Key Takeaway Messages

    • Pembrolizumab + chemotherapy without radiotherapy achieved a 2-year PFS rate of 67% and ORR of 81%in unresectable, locally advanced NSCLC with PD-L1 ≥50%.
    • Deep responders (≥80% tumor shrinkage) had markedly superior outcomes (2-year PFS 86%).
    • PD-L1 ≥80% subgroup showed the highest benefit (2-year OS 92%).
    • Safety profile manageable, with no new immune-related toxicities and no treatment-related deaths.
    • Findings suggest a potential curative systemic therapy alternative for selected patients; a randomized comparison with chemoradiotherapy–durvalumab is warranted.

    You Can Read Full Article Here

    Continue Reading

  • Indian central bank steps in to help rupee avert fall past record low, traders say – Reuters

    1. Indian central bank steps in to help rupee avert fall past record low, traders say  Reuters
    2. India rupee prone to fall past record low, rate outlook key for bond yields  TradingView
    3. Rupee gains 5 paise to 88.64 against US dollar in early trade  Press Trust of India
    4. Rupee Flat at 88.69: Weak Equities, Firm Dollar, Oil Prices Impact  Deccan Herald
    5. Indian Rupee Slips As US Dollar Strengthens Again  Finimize

    Continue Reading

  • Singapore set to introduce three-tier workplace dispute process

    Singapore set to introduce three-tier workplace dispute process

    The Workplace Fairness (Dispute Resolution) Bill (49-page / 209KB PDF) is the second piece of legislation under the Workplace Fairness Act (WFA) and was introduced in parliament on 14 October 2025, with the aim of promoting fair treatment within the workplace and smooth adjudication of disputes. If passed, it is expected to take effect by 2027.

    Mayumi Soh, an expert in employment law at Pinsent Masons, said: “Employers should take note of the three-tiered framework for resolving workplace disputes and consider whether any changes will be required to its internal standard operating procedures.”

    The WFA will generally apply to employers with 25 or more employees in Singapore at the initial stage. However, the Tripartite Guidelines on Fair Employment Practices will continue to apply to all employers regardless of their size.

    “Employers and their HR teams in Singapore should also review their internal grievances procedures, if any, to ensure compliance with the new WFA legislation. Even if an employer does not meet the current minimum threshold of 25 employees, it is good practice to put in place a grievance policy to ensure that there is a formal and consistent way which the employer will consider and review potential claims,” Soh said.

    The bill also prohibits adverse employment decisions based on 11 protected characteristics:  age, nationality, sex, marital status, race, religion, pregnancy, language ability, and caregiving responsibilities, disability or mental health condition.

    Under the legislation, employees who believe they have been discriminated against can raise the issue through their employer’s internal grievance-handling processes. This step aims to ensure any miscommunications are clarified and to help preserve employment relationships where possible.

    If the matter remains unresolved, the employee and their employer can proceed to mediation, seeking mutually agreeable outcomes within a prescribed period of time.
    Finally, employees can seek adjudication through the Employment Claims Tribunal (ECT) or the High Court. The bill proposes to expand the ECT’s monetary jurisdiction from a maximum of S$30,000 (approx. US$23,196) to S$250,000 (approx. US$192,875) for discrimination claims under the WFA, with the High Court handling claims above this threshold.

    Soh said: “We understand that the higher threshold is to ensure that majority of the cases can be addressed by ECT instead of going to court. It should be noted however, that it is expected that lawyers will not be able to represent employers at the ECT, similar to the current position.”

    Continue Reading

  • “It’s Time to Buy the Stock of Starbucks”

    “It’s Time to Buy the Stock of Starbucks”

    Starbucks Corporation (NASDAQ:SBUX) is one of the stocks Jim Cramer spoke about recently. Cramer mentioned his discussion with the company CEO, as he commented:

    “Starbucks, now under Brian Niccol, we’re slightly more than a year into his tenure, and after some fits and starts, this morning on Squawk on the Street, he told me that he’s finally ahead of plan… How’s Brian doing it? He’s doing it the Niccol way, taking care of service first. He’s got the scale. He’s got the biggest chain. He’s got the biggest drive-through, the biggest delivery. He just needed to staff all these businesses correctly… Throughput, he explained to me once, is the name of the game. You get that right, it can all come together… I wanted to come out here with something conclusive, conclusively positive about Starbucks. I simply didn’t have the confidence to truly stick my neck out… But now, with the Chinese business about to get a big partner and with cadence improving at the stores, I think it’s all coming together. Few believe the environment’s gotten tougher. Many restaurant chains have disappointed. So the turn of Starbucks is being overlooked. I’m betting that won’t last for long… What are you waiting for? It’s time to buy the stock of Starbucks.”

    Pixabay/Public Domain

    Starbucks Corporation (NASDAQ:SBUX) sells coffee, tea, and food products. The company operates through brands, including Starbucks Coffee, Teavana, and Seattle’s Best Coffee.

    While we acknowledge the potential of SBUX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

    READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

    Disclosure: None. This article is originally published at Insider Monkey.

    Continue Reading

  • Dollar strength keeps rupee on back foot; RBI counted on for support

    Dollar strength keeps rupee on back foot; RBI counted on for support

    MUMBAI, Nov 3(Reuters) – The Indian rupee faces renewed pressure on Monday following a fresh rally in the dollar, though expectations of central bank support are seen keeping the currency from slipping to a record low at open.

    The one-month non-deliverable forward (NDF) indicated the rupee will open in the 88.74–88.78 range to the dollar, compared with Friday’s level of 88.7650, just shy of the lifetime low of 88.80 hit in mid-October.

    Sign up here.

    The rupee has slipped back to its weakest levels after a brief respite engineered by heavy central bank intervention about two weeks ago. The intervention had helped the currency rally to near the 87.60 level.

    Bankers said persistent importer hedging, NDF expiries and renewed strength in the dollar have all contributed to the renewed pressure on the local unit.

    The Reserve Bank of India has appeared active in the latest phase of the rupee’s decline, with traders citing its presence through state-run banks.

    However, bankers said the central bank does not seem to be defending any specific level.

    “While they haven’t defended any particular level recently, I would expect the RBI to step in around 88.80,” a trader at a private bank said.

    “That’s where they acted last time, and staying away now could risk a large move higher (on dollar/rupee).”

    FED BOOST TO DOLLAR

    The dollar index firmed to a near three-month high on Monday, as expectations of a December rate cut by the Federal Reserve faded.

    A series of Fed officials on Friday voiced unease over the central bank’s decision to cut policy rates last week, reinforcing Chair Jerome Powell’s remark that a rate cut in December is “not a foregone conclusion, far from it.”

    Market pricing now implies roughly a two-in-three chance of a cut next month, down from nearly 90% before Powell’s remarks.

    KEY INDICATORS:

    ** One-month non-deliverable rupee forward at 88.84/88.90; onshore one-month forward premium at 13.25 paise

    ** Dollar index at 99.74

    ** Brent crude futures up 0.5% at $65.1 per barrel

    ** Ten-year U.S. note yield at 4.08%

    ** As per NSDL data, foreign investors sold a net $288.1 million worth of Indian shares on Oct 30

    ** NSDL data shows foreign investors sold a net $86 million worth of Indian bonds on Oct. 30

    Reporting by Nimesh Vora; Editing by Eileen Soreng

    Our Standards: The Thomson Reuters Trust Principles., opens new tab

    Continue Reading

  • Tribune Resources’ (ASX:TBR) investors will be pleased with their splendid 151% return over the last three years

    Tribune Resources’ (ASX:TBR) investors will be pleased with their splendid 151% return over the last three years

    The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put in. But if you buy shares in a really great company, you can more than double your money. For example, the Tribune Resources Limited (ASX:TBR) share price has soared 126% in the last three years. That sort of return is as solid as granite. On top of that, the share price is up 42% in about a quarter.

    So let’s investigate and see if the longer term performance of the company has been in line with the underlying business’ progress.

    This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

    In his essay The Superinvestors of Graham-and-Doddsville Warren Buffett described how share prices do not always rationally reflect the value of a business. One way to examine how market sentiment has changed over time is to look at the interaction between a company’s share price and its earnings per share (EPS).

    During three years of share price growth, Tribune Resources achieved compound earnings per share growth of 164% per year. This EPS growth is higher than the 31% average annual increase in the share price. So it seems investors have become more cautious about the company, over time. We’d venture the lowish P/E ratio of 10.50 also reflects the negative sentiment around the stock.

    You can see how EPS has changed over time in the image below (click on the chart to see the exact values).

    ASX:TBR Earnings Per Share Growth November 3rd 2025

    We’re pleased to report that the CEO is remunerated more modestly than most CEOs at similarly capitalized companies. It’s always worth keeping an eye on CEO pay, but a more important question is whether the company will grow earnings throughout the years. It might be well worthwhile taking a look at our free report on Tribune Resources’ earnings, revenue and cash flow.

    When looking at investment returns, it is important to consider the difference between total shareholder return (TSR) and share price return. The TSR incorporates the value of any spin-offs or discounted capital raisings, along with any dividends, based on the assumption that the dividends are reinvested. It’s fair to say that the TSR gives a more complete picture for stocks that pay a dividend. In the case of Tribune Resources, it has a TSR of 151% for the last 3 years. That exceeds its share price return that we previously mentioned. And there’s no prize for guessing that the dividend payments largely explain the divergence!

    It’s good to see that Tribune Resources has rewarded shareholders with a total shareholder return of 42% in the last twelve months. That’s including the dividend. That gain is better than the annual TSR over five years, which is 3%. Therefore it seems like sentiment around the company has been positive lately. Given the share price momentum remains strong, it might be worth taking a closer look at the stock, lest you miss an opportunity. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Even so, be aware that Tribune Resources is showing 1 warning sign in our investment analysis , you should know about…

    For those who like to find winning investments this free list of undervalued companies with recent insider purchasing, could be just the ticket.

    Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Australian exchanges.

    Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

    Continue Reading

  • Predicting the optimal timing for triggering in controlled ovarian stimulation: mature oocytes retrieval predictor | Reproductive Biology and Endocrinology

    Predicting the optimal timing for triggering in controlled ovarian stimulation: mature oocytes retrieval predictor | Reproductive Biology and Endocrinology

  • Thornton KL. Advances in assisted reproductive technologies. Obstet Gynecol Clin North Am. 2000;27:517–27.

    CAS 
    PubMed 

    Google Scholar 

  • Hu X, Luo Y, Huang K, Li Y, Xu Y, Zhou C, et al. New perspectives on criteria for the determination of HCG trigger timing in GnRH antagonist cycles. Medicine (Baltimore). 2016;95:e3691.

    CAS 
    PubMed 

    Google Scholar 

  • Poulain M, Younes R, Pirtea P, Trichereau J, de Ziegler D, Benammar A, et al. Impact of ovarian yield-number of total and mature oocytes per antral follicular count-on live birth occurrence after IVF treatment. Front Med. 2021;8:702010.

    Google Scholar 

  • Maheshwari A, McLernon D, Bhattacharya S. Cumulative live birth rate: time for a consensus? Hum Reprod. 2015;30:2703–7.

    PubMed 

    Google Scholar 

  • Germond M, Urner F, Chanson A, Primi MP, Wirthner D, Senn A. What is the most relevant standard of success in assisted reproduction? The cumulated singleton/twin delivery rates per oocyte pick-up: the CUSIDERA and CUTWIDERA. Hum Reprod. 2004;19(11):2442–4.

    PubMed 

    Google Scholar 

  • Vaughan DA, Leung A, Resetkova N, Ruthazer R, Penzias AS, Sakkas D, et al. How many oocytes are optimal to achieve multiple live births with one stimulation cycle? The one-and-done approach. Fertil Steril. 2017;107:397–e4043.

    PubMed 

    Google Scholar 

  • Polyzos NP, Drakopoulos P, Parra J, Pellicer A, Santos-Ribeiro S, Tournaye H, et al. Cumulative live birth rates according to the number of oocytes retrieved after the first ovarian stimulation for in vitro fertilization/intracytoplasmic sperm injection: a multicenter multinational analysis including ∼15,000 women. Fertil Steril. 2018;110:661–e6701.

    PubMed 

    Google Scholar 

  • Wu CX, Zhang T, Shu L, Huang J, Diao FY, Ding W, et al. [Cumulative live birth rates per oocytes retrieved cycle: evaluation of clinical outcomes of IVF/ICSI]. Zhonghua Fu Chan Ke Za Zhi. 2018;53:160–6. Chinese.

    CAS 
    PubMed 

    Google Scholar 

  • Drakopoulos P, Errázuriz J, Santos-Ribeiro S, Tournaye H, Vaiarelli A, Pluchino N, et al. Cumulative live birth rates in in-vitro fertilization. Minerva Ginecol. 2019;71:207–10.

    PubMed 

    Google Scholar 

  • Bosch E, Ezcurra D. Individualised controlled ovarian stimulation (iCOS): maximising success rates for assisted reproductive technology patients. Reprod Biol Endocrinol. 2011;9:82.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Popovic-Todorovic B, Loft A, Lindhard A, Bangsbøll S, Andersson AM, Andersen AN. A prospective study of predictive factors of ovarian response in ‘standard’ IVF/ICSI patients treated with Recombinant FSH. A suggestion for a Recombinant FSH dosage normogram. Hum Reprod. 2003;18:781–7.

    CAS 
    PubMed 

    Google Scholar 

  • Howles CM, Saunders H, Alam V, Engrand P, FSH Treatment Guidelines Clinical Panel. Predictive factors and a corresponding treatment algorithm for controlled ovarian stimulation in patients treated with Recombinant human follicle stimulating hormone (follitropin alfa) during assisted reproduction technology (ART) procedures. An analysis of 1378 patients. Curr Med Res Opin. 2006;22:907–18.

    CAS 
    PubMed 

    Google Scholar 

  • Yovich J, Stanger J, Hinchliffe P. Targeted gonadotrophin stimulation using the PIVET algorithm markedly reduces the risk of OHSS. Reprod Biomed Online. 2012;24:281–92.

    CAS 
    PubMed 

    Google Scholar 

  • Arce J-C, La Marca A, Mirner Klein B, Nyboe Andersen A, Fleming R. Antimüllerian hormone in gonadotropin releasing-hormone antagonist cycles: prediction of ovarian response and cumulative treatment outcome in good-prognosis patients. Fertil Steril. 2013;99:1644–53.

    CAS 
    PubMed 

    Google Scholar 

  • Lan VTN, Linh NK, Tuong HM, Wong PC, Howles CM. Anti-Müllerian hormone versus antral follicle count for defining the starting dose of FSH. Reprod Biomed Online. 2013;27:390–9.

    CAS 
    PubMed 

    Google Scholar 

  • Magnusson Å, Nilsson L, Oleröd G, Thurin-Kjellberg A, Bergh C. The addition of anti-Müllerian hormone in an algorithm for individualized hormone dosage did not improve the prediction of ovarian response—a randomized, controlled trial. Hum Reprod. 2017;32:811–9.

    CAS 
    PubMed 

    Google Scholar 

  • Harrison RF, Jacob S, Spillane H, Mallon E, Hennelly B. A prospective randomized clinical trial of differing starter doses of Recombinant follicle-stimulating hormone (follitropin-beta) for first time in vitro fertilization and intracytoplasmic sperm injection treatment cycles. Fertil Steril. 2001;75:23–31.

    CAS 
    PubMed 

    Google Scholar 

  • Klinkert ER, Broekmans FJ, Looman CW, Habbema JD, te Velde ER. Expected poor responders on the basis of an antral follicle count do not benefit from a higher starting dose of gonadotrophins in IVF treatment: a randomized controlled trial. Hum Reprod. 2005;20:611–5.

    CAS 
    PubMed 

    Google Scholar 

  • Lekamge DN, Lane M, Gilchrist RB, Tremellen KP. Increased gonadotrophin stimulation does not improve IVF outcomes in patients with predicted poor ovarian reserve. J Assist Reprod Genet. 2008;25:515–21.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Olivennes F, Howles CM, Borini A, Germond M, Trew G, Wikland M, et al. Individualizing FSH dose for assisted reproduction using a novel algorithm: the CONSORT study. Reprod Biomed Online. 2009;18:195–204.

    CAS 
    PubMed 

    Google Scholar 

  • Alviggi C, Conforti A, Esteves SC, Vallone R, Venturella R, Staiano S, et al. Understanding ovarian hypo-response to exogenous gonadotropin in ovarian stimulation and its new proposed marker-the follicle-to-oocyte (FOI) index. Front Endocrinol (Lausanne). 2018;9:589.

    PubMed 

    Google Scholar 

  • Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale, NJ: Lawrence Erlbaum Associates; 1988.

    Google Scholar 

  • Kobanawa M. The gonadotropins starting dose calculator, which can be adjusted the target number of oocytes and stimulation duration days to achieve individualized controlled ovarian stimulation in Japanese patients. Reprod Med Biol. 2023;22:e12499.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Iliodromiti S, Salje B, Dewailly D, Fairburn C, Fanchin R, Fleming R, et al. Non-equivalence of anti-Müllerian hormone automated assays-clinical implications for use as a companion diagnostic for individualised gonadotrophin dosing. Hum Reprod. 2017;32:1710–5.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Efron B. An introduction to the bootstrap. New York: Chapman & Hall; 1993.

    Google Scholar 

  • Friedman J, Hastie T, Tibshirani R. Regularization paths for generalized linear models via coordinate descent. J Stat Softw. 2010;33(1):1–22.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transpl. 2013;48:452–8.

    CAS 

    Google Scholar 

  • Calconic. (2025). Calconic – Custom Online Calculators. Retrieved March 9, 2025, from https://www.calconic.com/

  • Vaiarelli A, Zacà C, Spadoni V, Cimadomo D, Conforti A, Alviggi C, et al. Clinical and laboratory key performance indicators in IVF: a consensus between the Italian society of fertility and sterility and reproductive medicine (SIFES-MR) and the Italian society of Embryology, reproduction and research (SIERR). J Assist Reprod Genet. 2023;40:1479–94.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Clinic PI, Working Group, Vlaisavljevic V, Apter S, Capalbo A, D’Angelo A, Gianaroli L, et al. The Maribor consensus: report of an expert meeting on the development of performance indicators for clinical practice in ART. Hum Reprod Open. 2021;2021:hoab022.

    Google Scholar 

  • Abbara A, Vuong LN, Ho VNA, Clarke SA, Jeffers L, Comninos AN, et al. Follicle size on day of trigger most likely to yield a mature oocyte. Front Endocrinol (Lausanne). 2018;9:193.

    PubMed 

    Google Scholar 

  • Fanton M, Cho JH, Baker VL, Loewke K. A higher number of oocytes retrieved is associated with an increase in fertilized oocytes, blastocysts, and cumulative live birth rates. Fertil Steril. 2023;119:762–9.

    CAS 
    PubMed 

    Google Scholar 

  • Drakopoulos P, Blockeel C, Stoop D, Camus M, de Vos M, Tournaye H, et al. Conventional ovarian stimulation and single embryo transfer for IVF/ICSI. How many oocytes do we need to maximize cumulative live birth rates after utilization of all fresh and frozen embryos? Hum Reprod. 2016;31:370–6.

    PubMed 

    Google Scholar 

  • Luke B, Brown MB, Wantman E, Lederman A, Gibbons W, Schattman GL, et al. Cumulative birth rates with linked assisted reproductive technology cycles. N Engl J Med. 2012;366:2483–91.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Canon C, Leibner L, Fanton M, Chang Z, Suraj V, Lee JA, et al. Optimizing oocyte yield utilizing a machine learning model for dose and trigger decisions, a multi-center, prospective study. Sci Rep. 2024;14:18721.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Letterie G, Mac Donald A. Artificial intelligence in in vitro fertilization: a computer decision support system for day-to-day management of ovarian stimulation during in vitro fertilization. Fertil Steril. 2020;114:1026–31.

    CAS 
    PubMed 

    Google Scholar 

  • Hariton E, Chi EA, Chi G, Morris JR, Braatz J, Rajpurkar P, et al. A machine learning algorithm can optimize the day of trigger to improve in vitro fertilization outcomes. Fertil Steril. 2021;116:1227–35.

    PubMed 

    Google Scholar 

  • Ectors FJ, Vanderzwalmen P, Van Hoeck J, Nijs M, Verhaegen G, Delvigne A, et al. Relationship of human follicular diameter with oocyte fertilization and development after in-vitro fertilization or intracytoplasmic sperm injection. Hum Reprod. 1997;12:2002–5.

    CAS 
    PubMed 

    Google Scholar 

  • Ovarian Stimulation TEGGO, Bosch E, Broer S, Griesinger G, Grynberg M, Humaidan P, et al. [ESHRE guideline]. ESHRE guideline: ovarian stimulation for IVF/ICSI†. Hum Reprod Open. 2020;2020:hoaa009.

    PubMed 

    Google Scholar 

  • Wittmaack FM, Kreger DO, Blasco L, Tureck RW, Mastroianni L Jr, Lessey BA. Effect of follicular size on oocyte retrieval, fertilization, cleavage, and embryo quality in in vitro fertilization cycles: a 6-year data collection. Fertil Steril. 1994;62:1205–10.

    CAS 
    PubMed 

    Google Scholar 

  • Wirleitner B, Okhowat J, Vištejnová L, Králíčková M, Karlíková M, Vanderzwalmen P, et al. Relationship between follicular volume and oocyte competence, blastocyst development and live-birth rate: optimal follicle size for oocyte retrieval. Ultrasound Obstet Gynecol. 2018;51(1):118–25.

    CAS 
    PubMed 

    Google Scholar 

  • McCulloh DH, Kutchukhidze N, Charkviani T, Zhorzholadze T, Barbakadze T, Munné S, et al. Follicle size indicates oocyte maturity and blastocyst formation but not blastocyst euploidy following controlled ovarian hyperstimulation of oocyte donors. Hum Reprod. 2020;35(3):545–56.

    CAS 
    PubMed 

    Google Scholar 

  • Teissier MP, Chable H, Paulhac S, Aubard Y. Comparison of follicle steroidogenesis from normal and polycystic ovaries in women undergoing IVF: relationship between steroid concentrations, follicle size, oocyte quality and fecundability. Hum Reprod. 2000;15:2471–7.

    CAS 
    PubMed 

    Google Scholar 

  • Maghraby H, Saleh H, Fourtia IL, Rasheed S, Elmahdy M, Abdelbadie AS, et al. The dilemma of the trigger timing in IVF: a review. Middle East Fertil Soc J. 2024;29:8.

    Google Scholar 

  • Shapiro BS, Rasouli MA, Verma K, Raman A, Garner FC, Aguirre M, et al. The effect of ovarian follicle size on oocyte and embryology outcomes. Fertil Steril. 2022;117:1170–6.

    PubMed 

    Google Scholar 

  • Lensen SF, Wilkinson J, Leijdekkers JA, La Marca A, Mol BWJ, Marjoribanks J, et al. Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing in vitro fertilisation plus intracytoplasmic sperm injection (IVF/ICSI). Cochrane Database Syst Rev. 2018;2:CD012693.

    PubMed 

    Google Scholar 

  • Alport B, Case A, Lim H, Baerwald A. Does the ovarian stimulation phase length predict in vitro fertilization outcomes? Int J Fertil Steril. 2011;5:134–41.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Tian LF, Tan J, Zou Y, Su Q, Li Y, Xu DF, et al. Mild starting dosage ovarian stimulation combined with a modified prolonged GnRH-a protocol improved IVF/ICSI outcomes in normal ovarian responders. Arch Med Sci. 2019;15:1294–300.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • La Marca A, Papaleo E, Grisendi V, Argento C, Giulini S, Volpe A. Development of a nomogram based on markers of ovarian reserve for the individualisation of the follicle-stimulating hormone starting dose in in vitro fertilisation cycles. BJOG. 2012;119:1171–9.

    CAS 
    PubMed 

    Google Scholar 

  • Barbakadze L, Kristesashvili J, Khonelidze N, Tsagareishvili G. The correlations of anti-Mullerian hormone, follicle-stimulating hormone and antral follicle count in different age groups of infertile women. Int J Fertil Steril. 2015;8:393–8.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Shahrokh Tehraninezhad E, Mehrabi F, Taati R, Kalantar V, Aziminekoo E, Tarafdari A. Analysis of ovarian reserve markers (AMH, FSH, AFC) in different age strata in IVF/ICSI patients. Int J Reprod Biomed. 2016;14:501–6.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Practice Committee of the American Society for Reproductive Medicine, Electronic address: asrm@asrm.org, practice committee of the American society for reproductive Medicine. Testing and interpreting measures of ovarian reserve: a committee opinion. Fertil Steril. 2020;114:1151–7.

    Google Scholar 

  • Tsakos E, Tolikas A, Daniilidis A, Asimakopoulos B. Predictive value of anti-Müllerian hormone, follicle-stimulating hormone and antral follicle count on the outcome of ovarian stimulation in women following GnRH-antagonist protocol for IVF/ET. Arch Gynecol Obstet. 2014;290:1249–53.

    CAS 
    PubMed 

    Google Scholar 

  • Del Gallego R, Lawrenz B, Ata B, Kalafat E, Melado L, Elkhatib I, et al. Association of ‘normal’ early follicular FSH concentrations with unexpected poor or suboptimal response when ovarian reserve markers are reassuring: a retrospective cohort study. Reprod Biomed Online. 2024;48:103701.

    CAS 
    PubMed 

    Google Scholar 

  • La Marca A, Papaleo E, Alviggi C, Ruvolo G, De Placido G, Candiani M, et al. The combination of genetic variants of the FSHB and FSHR genes affects serum FSH in women of reproductive age. Hum Reprod. 2013;28:1369–74.

    CAS 
    PubMed 

    Google Scholar 

  • Achrekar SK, Modi DN, Desai SK, Mangoli VS, Mangoli RV, Mahale SD. Poor ovarian response to gonadotrophin stimulation is associated with FSH receptor polymorphism. Reprod Biomed Online. 2009;18:509–15.

    CAS 
    PubMed 

    Google Scholar 

  • Sudo S, Kudo M, Wada S, Sato O, Hsueh AJW, Fujimoto S. Genetic and functional analyses of polymorphisms in the human FSH receptor gene. Mol Hum Reprod. 2002;8:893–9.

    CAS 
    PubMed 

    Google Scholar 

  • Perez Mayorga M, Gromoll J, Behre HM, Gassner C, Nieschlag E, Simoni M. Ovarian response to follicle-stimulating hormone (FSH) stimulation depends on the FSH receptor genotype. J Clin Endocrinol Metab. 2000;85:3365–9.

    CAS 
    PubMed 

    Google Scholar 

  • Jun JK, Yoon JS, Ku SY, Choi YM, Hwang KR, Park SY, et al. Follicle-stimulating hormone receptor gene polymorphism and ovarian responses to controlled ovarian hyperstimulation for IVF-ET. J Hum Genet. 2006;51:665–70.

    CAS 
    PubMed 

    Google Scholar 

  • Behre HM, Greb RR, Mempel A, Sonntag B, Kiesel L, Kaltwasser P, et al. Significance of a common single nucleotide polymorphism in exon 10 of the follicle-stimulating hormone (FSH) receptor gene for the ovarian response to FSH: a Pharmacogenetic approach to controlled ovarian hyperstimulation. Pharmacogenet Genomics. 2005;15:451–6.

    CAS 
    PubMed 

    Google Scholar 

  • Alviggi C, Conforti A, Esteves SC. Impact of mutations and polymorphisms of gonadotrophins and their receptors on the outcome of controlled ovarian stimulation. In: Ghumman S, ed. Principles and practice of controlled ovarian stimulation in ART. New Delhi: Springer, 2015. Available at: https://doi.org/10.1007/978-81-322-1686-5_14. Accessed November 18, 2024.

  • Alviggi C, Conforti A, Caprio F, Gizzo S, Noventa M, Strina I, et al. In estimated good prognosis patients could unexpected hyporesponse to controlled ovarian stimulation be related to genetic polymorphisms of FSH receptor? Reprod Sci. 2016;23:1103–8.

    CAS 
    PubMed 

    Google Scholar 

  • Olsson H, Sandström R, Grundemar L. Different pharmacokinetic and pharmacodynamic properties of recombinant follicle-stimulating hormone (rFSH) derived from a human cell line compared with rFSH from a non-human cell line. J Clin Pharmacol. 2014;54:1299–307.

    CAS 
    PubMed 

    Google Scholar 

  • FERRING INTERNATIONAL CENTER SA. WO2009127826 – Recombinant FSH including alpha 2,3 and alpha 2,6 sialylation. Available at: https://patentscope2.wipo.int/search/en/detail.jsf?docId=WO2009127826. Accessed November 30, 2022.

  • Nyboe Andersen A, Nelson SM, Fauser BC, García-Velasco JA, Klein BM, Arce JC, ESTHER-1 study group. Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial. Fertil Steril. 2017;107:387–e3964.

    CAS 
    PubMed 

    Google Scholar 

  • Qiao J, Zhang Y, Liang X, Ho T, Huang HY, Kim SH, et al. A randomised controlled trial to clinically validate follitropin delta in its individualised dosing regimen for ovarian stimulation in Asian IVF/ICSI patients. Hum Reprod. 2021;36:2452–62.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Kobanawa M, Yoshida J. Differences in follicle development and hormone dynamics between controlled ovarian stimulation (COS) using follitropin delta and that using follitropin alfa. FandR. 2023;05:79–86.

    Google Scholar 

  • Abbara A, Patel A, Hunjan T, Clarke SA, Chia G, Eng PC, et al. FSH requirements for follicle growth during controlled ovarian stimulation. Front Endocrinol (Lausanne). 2019;10:579.

    PubMed 

    Google Scholar 

  • van Weissenbruch MM, Schoemaker HC, Drexhage HA, Schoemaker J. Pharmaco-dynamics of human menopausal gonadotrophin (HMG) and follicle-stimulating hormone (FSH). The importance of the FSH concentration in initiating follicular growth in polycystic ovary-like disease. Hum Reprod. 1993;8:813–21.

    PubMed 

    Google Scholar 

  • Schipper I, Hop WC, Fauser BC. The follicle-stimulating hormone (FSH) threshold/window concept examined by different interventions with exogenous FSH during the follicular phase of the normal menstrual cycle: duration, rather than magnitude, of FSH increase affects follicle development. J Clin Endocrinol Metab. 1998;83:1292–8.

    CAS 
    PubMed 

    Google Scholar 

  • Macklon NS, Fauser BC. Follicle-stimulating hormone and advanced follicle development in the human. Arch Med Res. 2001;32:595–600.

    CAS 
    PubMed 

    Google Scholar 

  • de Koning CH, Schoemaker J, Lambalk CB. Estimation of the follicle-stimulating hormone (FSH) threshold for initiating the final stages of follicular development in women with elevated FSH levels in the early follicular phase. Fertil Steril. 2004;82:650–3.

    PubMed 

    Google Scholar 

  • Fatemi H, Bilger W, Denis D, Griesinger G, La Marca A, Longobardi S, et al. Dose adjustment of follicle-stimulating hormone (FSH) during ovarian stimulation as part of medically-assisted reproduction in clinical studies: a systematic review covering 10 years (2007–2017). Reprod Biol Endocrinol. 2021;19:68.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Noyes N, Fino ME, Krey L, McCaffrey C, Adler A, Grifo J. Embryo biopsy: the fate of abnormal pronuclear embryos. Reprod Biomed Online. 2008;17(6):782–8.

    PubMed 

    Google Scholar 

  • ESHRE Guideline Group on Good Practice in IVF Labs, De los Santos MJ, Apter S, Coticchio G, Debrock S, Lundin K, et al. Revised guidelines for good practice in IVF laboratories (2015). Hum Reprod. 2016;31(4):685–6.

    Google Scholar 

Continue Reading